Sanofi has signed an agreement to acquire Vicebio’s share capital for $1.15bn upfront, to expand its vaccine development capabilities.

French pharmaceuticals company Sanofi said on Tuesday it would acquire British private biotechnology firm Vicebio for a total ...

Sanofi acquires Vicebio for $1.15 billion, adding a next-gen RSV-hMPV vaccine and ‘Molecular Clamp' tech to strengthen its respiratory vaccine pipeline.